Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

기사 요약

Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.